Cancer Stem Cell News Volume 13.14 | May 29 2024

    0
    72








    2024-05-29 | CSCN 13.14


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 13.14 – 29 May, 2024
    TOP STORY

    BRG1/BRM Inhibitor Targets AML Stem Cells and Exerts Superior Preclinical Efficacy Combined with BET or Menin Inhibitor

    Investigators showed that FHD-286 induced differentiation and lethality in AML cells with MLL1 rearrangement or mutant NPM1, concomitantly causing perturbed chromatin accessibility and repression of c-Myc, PU.1, and CDK4/6.
    [Blood]

    Abstract
    PUBLICATIONSRanked by the impact factor of the journal

    Platelet-Mediated Circulating Tumor Cell Evasion from Natural Killer Cell Killing via Immune Checkpoint CD155-TIGIT

    Scientists identified circulating tumor cell-platelet adhesions by single-cell RNA sequencing and multiplex immunofluorescence of blood samples from multiple cancer types.
    [Hepatology]

    AbstractGraphical Abstract

    PA28γ Coordinates the Cross-Talk Between Cancer-Associated Fibroblasts and Tumor Cells to Promote OSCC Progression via HDAC1/E2F3/IGF2 Signaling

    Using oral squamous cell carcinoma as a model, the authors demonstrated that PA28γ exhibited high expression in cancer-associated fibroblasts, and its expression significantly correlated with the severity of clinical indicators of malignancy.
    [Cancer Letters]

    Abstract

    Selective Targeting of IRAK1 Attenuates Low Molecular Weight Hyaluronic Acid-Induced Stemness and Non-Canonical STAT3 Activation in Epithelial Ovarian Cancer

    Researchers showed that IRAK1 was upregulated in EOC tissues, and enhanced expression correlates with poorer overall survival.
    [Cell Death & Disease]

    Full Article

    PRMT5-Mediated Methylation of STAT3 Is Required for Lung Cancer Stem Cell Maintenance and Tumor Growth

    Investigators showed that PRMT5 directly methylated STAT3 and enhanced its activated tyrosine phosphorylation in non-small cell lung cancer cells.
    [Communications Biology]

    Full Article

    Vasorin Promotes Endothelial Differentiation of Glioma Stem Cells via Stimulating the Transcription of VEGFR2

    The authors showed that vasorin (VASN) expression positively correlated with glioma-derived endothelial cell signatures in glioma patients. VASN promoted the endothelial differentiation capacity of glioma stem cell (GSC) in vitro and participates in the formation of GSC-derived vessels in vivo.
    [FASEB Journal]

    Abstract

    Oridonin, a Small Molecule Inhibitor of Cancer Stem Cell with Potent Cytotoxicity and Differentiation Potential

    Researchers introduced oridonin, a small molecule with dual differentiation-inducing and cytotoxicity properties capable of eliminating tumor CSCs.
    [European Journal of Pharmacology]

    Abstract

    Knockdown of YTHDF2 Initiates ERS-Induced Apoptosis and Cancer Stemness Suppression by Sustaining GLI2 Stability in Cervical Cancer

    Investigators showed how YTH N6-methyladenosine RNA-binding protein F2 (YTHDF2) controlled the fate of cervical cancer cells and whether YTHDF2 could be a valid target for the therapy of cervical cancer.
    [Translational Oncology]

    Full Article

    Isolation and Phenotypic Characterization of Cancer Stem Cells From Metastatic Oral Cancer Cells

    E-cadherin levels were higher in CSC-E cells while vimentin and Slug more produced by CSC-M2 cells. CSC-M1 and CSC-M2 subpopulations showed higher proliferation, produced more colonies, and have stronger adhesion to the extracellular matrix.
    [Oral Diseases]

    Abstract
    A person presenting slides at a scientific conference
    REVIEWS

    Dark Force Rising: Reawakening and Targeting of Fetal-Like Stem Cells in Colorectal Cancer

    The authors discuss critical mechanisms facilitating the plasticity between stem cell states and highlight the heterogeneity observed upon the appearance of fetal-like states.
    [Cell Reports]

    Full Article
    INDUSTRY AND POLICY NEWS

    FDA Approves Amgen’s Treatment for Most Deadly Form of Lung Cancer

    The FDA cleared Amgen’s drug, called Imdelltra, as a second or later-line treatment for adults with advanced small-cell lung cancer.
    [CNBC]

    Press Release

    Providence and Ontario Institute for Cancer Research (OICR) Partnering to Discover and Develop mRNA Therapeutics

    Providence Therapeutic Holdings, Inc. and the Ontario Institute for Cancer Research announced the signing of a collaboration agreement for mRNA drug discovery and development.
    [Providence Therapeutics, Inc.]

    Press Release
    FEATURED EVENT

    AMP Europe 2024

    June 24 – 26, 2024
    Madrid, Spain

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Fellow – Cancer and Hematological Disorders

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Research Technician – ER+ Breast Cancer

    Baylor College of Medicine – Houston, Texas, United States

    PhD Scholarship – Immunomodulatory Properties of Natural Anti-Cancer Compounds

    RMIT University – Melbourne, Victoria, Australia

    Translational Scientist – Colorectal Cancer and Wnt Signaling

    CRUK Scotland Institute – Glasgow, Scotland, United Kingdom

    Postdoctoral Research Fellow – Prostate Cancer

    Dana Farber Cancer Institute – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2